Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2019 Mar 14

PMID 30863364

Citations 42

Authors

Sine Paasch Schiellerup

Kirsa Skov-Jeppesen

Johanne Agerlin Windelov

Maria Saur Svane

Jens Juul Holst

Bolette Hartmann

Mette Marie Rosenkilde

Affiliations

Soon will be listed here.

Abstract

Bone homeostasis displays a circadian rhythm with increased resorption during the night time as compared to day time, a difference that seems-at least partly-to be caused by food intake during the day. Thus, ingestion of a meal results in a decrease in bone resorption, but people suffering from short bowel syndrome lack this response. Gut hormones, released in response to a meal, contribute to this link between the gut and bone metabolism. The responsible hormones appear to include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), known as incretin hormones due to their role in regulating glucose homeostasis by enhancing insulin release in response to food intake. They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs), and already recognized as targets for treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide-2 (GLP-2), secreted concomitantly with GLP-1, acting via another class B receptor (GLP-2R), is also part of this gut-bone axis. Several studies, including human studies, have indicated that these three hormones inhibit bone resorption and, moreover, that GIP increases bone formation. Another hormone, peptide YY (PYY), is also secreted from the enteroendocrine L-cells (together with GLP-1 and GLP-2), and acts mainly via interaction with the class A GPCR NPY-R2. PYY is best known for its effect on appetite regulation, but recent studies have also shown an effect of PYY on bone metabolism. The aim of this review is to summarize the current knowledge of the actions of GIP, GLP-1, GLP-2, and PYY on bone metabolism, and to discuss future therapies targeting these receptors for the treatment of osteoporosis.

Citing Articles

Treatment with bariatric surgery in patients with osteogenesis imperfecta and severe obesity.

Hald J, Hald A, Harslof T, Langdahl B, Bruun J Bone Rep. 2024; 23:101811.

PMID: 39497944 PMC: 11532804. DOI: 10.1016/j.bonr.2024.101811.

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review.

Pechmann L, Pinheiro F, Andrade V, Moreira C Diabetol Metab Syndr. 2024; 16(1):175.

PMID: 39054499 PMC: 11270814. DOI: 10.1186/s13098-024-01412-x.

Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis.

Liu H, Xiao H, Lin S, Zhou H, Cheng Y, Xie B Front Pharmacol. 2024; 15:1372399.

PMID: 38725663 PMC: 11079205. DOI: 10.3389/fphar.2024.1372399.

Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus.

Ali A, Flatt P, Irwin N Clin Med Insights Endocrinol Diabetes. 2024; 17:11795514241238059.

PMID: 38486712 PMC: 10938612. DOI: 10.1177/11795514241238059.

Controlled mechanical loading affects the osteocyte transcriptome in porcine trabecular bone in situ.

Machireddy M, Oberman A, DeBiase L, Stephens M, Li J, Littlepage L Bone. 2024; 181:117028.

PMID: 38309412 PMC: 10923013. DOI: 10.1016/j.bone.2024.117028.

References

Nuche-Berenguer B, Portal-Nunez S, Moreno P, Gonzalez N, Acitores A, Lopez-Herradon A . Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol. 2010; 225(2):585-92. DOI: 10.1002/jcp.22243. View

Drucker D, Yusta B . Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2013; 76:561-83. DOI: 10.1146/annurev-physiol-021113-170317. View

Mieczkowska A, Mansur S, Bouvard B, Flatt P, Thorens B, Irwin N . Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength. Osteoporos Int. 2014; 26(1):209-18. DOI: 10.1007/s00198-014-2845-8. View

Torang S, Bojsen-Moller K, Svane M, Hartmann B, Rosenkilde M, Madsbad S . In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans. Am J Physiol Regul Integr Comp Physiol. 2016; 310(9):R866-74. PMC: 5000776. DOI: 10.1152/ajpregu.00394.2015. View

Torekov S, Harslof T, Rejnmark L, Eiken P, Jensen J, Herman A . A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab. 2014; 99(4):E729-33. DOI: 10.1210/jc.2013-3766. View

Haderslev K, Jeppesen P, Hartmann B, Thulesen J, Sorensen H, Graff J . Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol. 2002; 37(4):392-8. DOI: 10.1080/003655202317316006. View

Gottschalck I, Jeppesen P, Hartmann B, Holst J, Henriksen D . Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand J Gastroenterol. 2008; 43(11):1304-10. DOI: 10.1080/00365520802200028. View

Thulesen J, Knudsen L, Hartmann B, Hastrup S, Kissow H, Jeppesen P . The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept. 2001; 103(1):9-15. DOI: 10.1016/s0167-0115(01)00316-0. View

Gabe M, Sparre-Ulrich A, Pedersen M, Gasbjerg L, Inoue A, Brauner-Osborne H . Human GIP(3-30)NH inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochem Pharmacol. 2018; 150:97-107. DOI: 10.1016/j.bcp.2018.01.040. View

10.

Henriksen D, Alexandersen P, Hartmann B, Adrian C, Byrjalsen I, Bone H . Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009; 45(5):833-42. DOI: 10.1016/j.bone.2009.07.008. View

11.

Westberg-Rasmussen S, Starup-Linde J, Hermansen K, Holst J, Hartmann B, Vestergaard P . Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone. 2017; 97:261-266. DOI: 10.1016/j.bone.2017.01.027. View

12.

Hansen L, Sparre-Ulrich A, Christensen M, Knop F, Hartmann B, Holst J . N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor. Br J Pharmacol. 2015; 173(5):826-38. PMC: 4761099. DOI: 10.1111/bph.13384. View

13.

Feng Y, Su L, Zhong X, Guohong W, Xiao H, Li Y . Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation. J Mol Endocrinol. 2015; 56(3):189-99. DOI: 10.1530/JME-15-0264. View

14.

Hartmann B, Harr M, Jeppesen P, Wojdemann M, Deacon C, Mortensen P . In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 2000; 85(8):2884-8. DOI: 10.1210/jcem.85.8.6717. View

15.

Zhong Q, Itokawa T, Sridhar S, Ding K, Xie D, Kang B . Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2006; 292(2):E543-8. DOI: 10.1152/ajpendo.00364.2006. View

16.

Silva M, Gibson L . Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Bone. 1997; 21(2):191-9. DOI: 10.1016/s8756-3282(97)00100-2. View

17.

PERLEY M, KIPNIS D . Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest. 1967; 46(12):1954-62. PMC: 292948. DOI: 10.1172/JCI105685. View

18.

Finan B, Yang B, Ottaway N, Smiley D, Ma T, Clemmensen C . A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2014; 21(1):27-36. DOI: 10.1038/nm.3761. View

19.

Veedfald S, Plamboeck A, Deacon C, Hartmann B, Knop F, Vilsboll T . Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. Am J Physiol Gastrointest Liver Physiol. 2015; 310(1):G43-51. DOI: 10.1152/ajpgi.00222.2015. View

20.

Gottschalck I, Jeppesen P, Holst J, Henriksen D . Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scand J Gastroenterol. 2008; 43(8):929-37. DOI: 10.1080/00365520801965381. View